Kymab Group Limited
Kymab Group Limited, a pioneering biotechnology company headquartered in Great Britain, focuses on the development of innovative therapeutic antibodies. Founded in 2010, Kymab has made significant strides in the biopharmaceutical industry, particularly in the fields of immunology and oncology. The company is renowned for its proprietary Kymab platform, which enables the rapid discovery and development of monoclonal antibodies with unique properties. Kymab's lead product, KY1005, is designed to modulate immune responses, showcasing the company's commitment to addressing unmet medical needs. With a strong market position bolstered by strategic partnerships and a robust pipeline, Kymab continues to be a key player in advancing next-generation therapies, contributing to the evolution of modern medicine.
DitchCarbon Score
How does Kymab Group Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kymab Group Limited's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kymab Group Limited's reported carbon emissions
Kymab Group Limited, headquartered in Great Britain, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As such, Kymab's climate commitments and initiatives remain unspecified, and there is no inherited emissions data from a parent or related organization. Without available data, it is unclear how Kymab is addressing climate change or its carbon footprint within the biopharmaceutical industry context.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kymab Group Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
